MN-166 (ibudilast)
Progressive Multiple Sclerosis
Key Facts
About MediciNova
MediciNova employs a capital-efficient 'search and develop' model, building a pipeline through strategic in-licensing of clinical-stage compounds. Founded in 2000 with Japanese venture backing, it has achieved dual public listings on NASDAQ and the Osaka Exchange. The company's current strategic focus is on three core assets: MN-166 (ibudilast) for neurological disorders, MN-221 for acute asthma/COPD exacerbations, and MN-001 for fibrotic diseases, aiming to create value through clinical milestones and strategic partnerships.
View full company profileAbout MediciNova
MediciNova employs a capital-efficient 'search and develop' model, building a pipeline through strategic in-licensing of clinical-stage compounds. Founded in 2000 with Japanese venture backing, it has achieved dual public listings on NASDAQ and the Osaka Exchange. The company's current strategic focus is on three core assets: MN-166 (ibudilast) for neurological disorders, MN-221 for acute asthma/COPD exacerbations, and MN-001 for fibrotic diseases, aiming to create value through clinical milestones and strategic partnerships.
View full company profileAbout MediciNova
MediciNova employs a capital-efficient 'search and develop' model, building a pipeline through strategic in-licensing of clinical-stage compounds. Founded in 2000 with Japanese venture backing, it has achieved dual public listings on NASDAQ and the Osaka Exchange. The company's current strategic focus is on three core assets: MN-166 (ibudilast) for neurological disorders, MN-221 for acute asthma/COPD exacerbations, and MN-001 for fibrotic diseases, aiming to create value through clinical milestones and strategic partnerships.
View full company profileTherapeutic Areas
Other Progressive Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| PIPE-791 | Contineum Therapeutics | Phase 1 |